The diluted equity raise at a depressed price while cash runway only extends into Q3 2026 signals acute financing need. Combined with failed IPR petitions against Inspire and a CEO transition, the risk/reward is unfavorable for existing holders. Traders should expect further downside pressure as the offering prices and overhang materializes.
Price Chart
Executive Summary
Nyxoah filed a preliminary prospectus supplement (424B5) for an underwritten follow-on offering of ordinary shares, with pricing to be determined after the June 3, 2026 closing price of $2.85/share. The offering size is undisclosed. The company disclosed a cash runway extending only into Q3 2026, an accumulated deficit of €321.7M, and that its IPR petitions against Inspire were denied. Concurrently, the company announced a CEO transition to a U.S.-based successor, adding leadership uncertainty.
Key Facts
- 424B5 filing for an underwritten follow-on public offering of ordinary shares; share count, price, and gross proceeds are all undisclosed placeholder amounts.
- Stock price at last sale on Nasdaq was $2.85 on June 3, 2026, down ~75% from the $11.33 reference price in the base prospectus from April 1, 2025.
- Cash, cash equivalents, and financial assets totaled €25.9M as of March 31, 2026; accumulated deficit was €321.7M.
- Cash runway expected only into Q3 2026, even after drawing the second tranche of the €13.8M EIB loan.
- IPR petitions against Inspire Medical Systems' patents were denied institution on April 14, 2026, weakening Nyxoah's litigation position.
- CEO Olivier Taelman is transitioning out; a search for a U.S.-based CEO has been launched, creating leadership uncertainty during a capital raise.
- Existing stockholders affiliated with directors have indicated non-binding interest in purchasing shares.
- Underwriters granted a 30-day over-allotment option; 90-day lock-up for company, directors, and officers.
Financial Impact
Undisclosed offering size; at the $2.85 reference price, investors face immediate and substantial dilution given negative tangible book value of -$0.36/share.
Risk Factors
- Significant dilution from the offering at a low stock price; net tangible book value is already negative.
- Cash runway only into Q3 2026 suggests another capital raise will be needed soon after this one.
- Denied IPR petitions weaken Nyxoah's defense against Inspire's patent infringement lawsuit, increasing legal overhang.
- CEO transition adds execution risk during a critical commercial ramp in the U.S.
- Reimbursement and coding uncertainty for the Genio system remains a headwind to U.S. adoption.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-070509 |
| Document: 0001104659-26-070509-index-headers.html | 0001104659-26-070509 |
| Document: 0001104659-26-070509-index.html | 0001104659-26-070509 |
| Document: 0001104659-26-070509.txt | 0001104659-26-070509 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 6-K | $0.8950 $0.8220 | ▲ +8.16% | ▲ +6.98% | $0.8560 (+4.36%) |
Oct 19, 2026 7d ago | Press Release | $0.9540 $0.9400 | ▲ +1.47% | ▲ +1.80% | $0.8560 (+10.27%) |
Sep 22, 2026 4w ago | 6-K | $1.33 $1.27 | ▼ −4.51% | ▼ −4.43% | $0.8560 (−35.64%) |
Jun 23, 2026 17w ago | 6-K | $1.62 $1.63 | ▼ −0.62% | ▼ −0.47% | $0.8560 (+47.16%) |
Jun 11, 2026 19w ago | 6-K | $1.39 $1.55 | ▼ −11.51% | ▼ −9.75% | $0.8560 (+38.42%) |
Jun 8, 2026 20w ago | 6-K | $1.34 $1.31 | ▲ +2.24% | ▲ +0.66% | $0.8560 (+36.12%) |
Jun 8, 2026 20w ago | 424B5 | $1.39 $1.34 | ▲ +3.60% | ▲ +3.30% | $0.8560 (+38.42%) |
Jun 5, 2026 20w ago | Press Release | $1.45 $1.39 | ▲ +4.14% | ▲ +4.36% | $0.8560 (+40.97%) |
Jun 4, 2026 20w ago | 424B5 | $1.45 $1.39 | ▲ +4.14% | ▲ +4.36% | $0.8560 (+40.97%) |
May 20, 2026 22w ago | Press Release | $2.87 $2.87 | · 0.00% | ▼ −0.45% | $0.8560 (−70.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers